Get the Stockscreener App
55.14
3.82%
2.03
After Hours:
55.68
0.54
+0.98%
Structure Therapeutics Inc Adr stock is traded at $55.14, with a volume of 589.24K.
It is up +3.82% in the last 24 hours and down -2.41% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$53.11
Open:
$52.25
24h Volume:
589.24K
Relative Volume:
0.57
Market Cap:
$3.91B
Revenue:
-
Net Income/Loss:
$-141.43M
P/E Ratio:
-22.43
EPS:
-2.4581
Net Cash Flow:
$-226.41M
1W Performance:
+3.10%
1M Performance:
-2.41%
6M Performance:
+80.49%
1Y Performance:
+261.10%
1-Day Range:
$52.25
$55.84
1-Week Range:
$50.23
$57.23
52-Week Range:
$14.42
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
55.14 | 3.76B | 0 | -141.43M | -226.41M | -2.4581 |
VRTX
Vertex Pharmaceuticals Inc
|
446.78 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
767.85 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.50 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.28 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.42 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Why Structure Therapeutics Stock Is Suddenly Sinking - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Why Structure Therapeutics Stock Suddenly Took Off Today - TipRanks
Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Why Structure Therapeutics (GPCR) Is Up 21.7% After Promising Phase 2 Oral Obesity Drug Data - Sahm
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Structure Therapeutics Stock Is Suddenly Surging - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8%What's Next? - MarketBeat
LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill? - TradingView
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail
Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Sahm
Structure Therapeutics Stock Jumps on Obesity Drug Buzz - TipRanks
Structure Therapeutics Shares Surge on Obesity Drug Breakthrough - TipRanks
Structure Therapeutics (GPCR) Is Down 5.5% After Strong Oral GLP-1 Phase 2 DataWhat's Changed - Sahm
Structure Therapeutics (NASDAQ:GPCR) Stock Rating Lowered by Wall Street Zen - MarketBeat
Structure Therapeutics Obesity Trial Success Puts Valuation Gap In Focus - Sahm
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at Wolfe Research - MarketBeat
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Wolfe Research initiates Structure Therapeutics stock rating at Peerperform By Investing.com - Investing.com India
Wolfe Research initiates Structure Therapeutics stock rating at Peerperform - Investing.com
GPCR SEC FilingsStructure Therapeutics Inc ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) awards new options and RSUs - Stock Titan
Structure Therapeutics (GPCR) CMO receives new stock options and RSU grants - Stock Titan
Structure Therapeutics (GPCR) CTO awarded options and 32,526 RSUs - Stock Titan
Structure Therapeutics (GPCR) grants CSO new stock options and RSUs - Stock Titan
Structure Therapeutics (GPCR) CFO receives large option and RSU grants - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) CEO awarded new options and 260,217 RSUs - Stock Titan
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? - Yahoo Finance
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges - AOL.com
B Group Acquires 4.62% Portfolio Stake in Structure Therapeutics | 2025 InvestmentNews and Statistics - IndexBox
LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Electrocore (ECOR) - The Globe and Mail
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
Did Positive Phase 2 Aleniglipron Data Just Shift Structure Therapeutics' (GPCR) Investment Narrative? - Sahm
How (GPCR) Movements Inform Risk Allocation Models - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.5%Should You Sell? - MarketBeat
Why Structure Therapeutics Shares Are Tumbling Today - TipRanks
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
What is HC Wainwright's Forecast for GPCR FY2027 Earnings? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III - MarketBeat
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
H.C. Wainwright lowers Structure Therapeutics price target on penetration assumptions - Investing.com
Citizens reiterates Structure Therapeutics stock rating on weight loss data - Investing.com
Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test - MedCity News
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):